Top-ranked for the last 18 years, our cardiovascular program is led by some of the country’s most experienced and respected physicians and surgeons.
With dedicated heart centers and a team at the forefront of medical innovation and research, our cardiovascular services make us a leading program in the nation for the treatment of structural heart, aortic, heart failure, and vascular disorders.
Cardiology & Heart Surgery
This recap of 2022 highlights NewYork-Presbyterian’s pioneering clinical treatments and scientific endeavors to maximize outcomes for patients with all levels of heart disease complexity.
CIED-Associated Infections: An Imperative for Increasing Utilization of Device Removal
A Weill Cornell Medicine electrophysiologist presents significant findings from research uncovering the infrequent use of lead extraction and system removal despite recognition as the optimal treatment for endocarditis.
Total Artificial Heart Revolutionizes Heart Transplant Surgery
A Columbia cardiothoracic surgeon performs a total artificial heart implant in the first pediatric patient in the northeast.
Study Led at NewYork-Presbyterian Demonstrates Consistent Reduction in Blood Pressure with Ultrasound Renal Denervation
A Columbia interventional cardiologist leads a multicenter study validating the use of the procedure as an adjunct to current therapies for reducing hypertension in selected patients.
Women Fare Worse than Men Undergoing CABG: Time to Close the Gap
A Weill Cornell Medicine cardiothoracic surgeon leads a study that confirms that the outcomes for women undergoing coronary artery bypass graft (CABG) surgery remain inferior to those of men and launches a new clinical trial for women to address this discrepancy.
NewYork-Presbyterian Researchers Are Getting to the Heart of the Fight-or-Flight Response
Cardiology faculty from NewYork-Presbyterian/Columbia have identified the molecules involved in cardiac contractility, finding a new target for heart failure treatment.
Deciphering the Connection of Serotonin to Degenerative Mitral Valve Regurgitation
A study by Columbia research scientists reveals how serotonin facilitates progression of mitral valve disease.
For Women Only: A Study of Intravascular Lithotripsy for Coronary Artery Calcification
A Columbia interventional cardiologist investigates the outcomes of intravascular lithotripsy in a first-ever study focused on an all female cohort.
Novel Nasal Spray Medication May Transform Treatment for Supraventricular Tachycardia
A Weill Cornell Medicine electrophysiologist is a primary investigator on clinical trials testing etripamil, an investigational drug that can be self-administered by patients at home to control spontaneous paroxysmal supraventricular tachycardia.
Tricuspid Valve Surgery: Clarifying Outcomes for Patients with Non-Ebstein Disease
Columbia cardiac surgeon leads research to better understand outcomes and risk factors related to tricuspid valve disease surgery in patients with congenital heart disease, particularly non-Ebstein 2-ventricle congenital tricuspid valve disease.
ECMO for Postcardiotomy Shock: Investigating Outcomes and Adverse Events
Columbia cardiac surgery faculty in collaboration with specialists in heart failure and critical care medicine conduct comprehensive studies of ECMO when used in patients developing postcardiotomy shock.
Can Cardiac Implantable Electronic Devices Detect Early Onset of COVID-19?
Columbia and Weill Cornell Medicine cardiologists and heart failure specialists investigate CIED sensor data for physiologic changes that may enable earlier identification of acute COVID-19 facilitating timelier intervention.
Identifying the Finer Points of Aortic Valve-Sparing Root Replacement
Weill Cornell Medicine’s cardiothoracic surgeons evaluate the many nuances of the valve-sparing procedure to better understand factors affecting the durability of the native aortic valve.
Hypertrophic Cardiomyopathy: Addressing the Compelling Need for Warning Signals
A Columbia cardiologist specializing in HCM applies the novel technology of proteomics profiling to address shortcomings in predicting and understanding major adverse cardiovascular events in patients with this life-threatening disease.
A Major Milestone for LVADs: Extending Survival for Heart Failure Patients
Columbia and Weill Cornell Medicine LVAD investigators report on the findings of the extended-phase MOMENTUM 3 study.
Benefit vs. Risk in Dual Antiplatelet Therapy After CABG
A Weill Cornell Medicine cardiothoracic surgeon led a study of a dual antiplatelet therapy that was found to reduce the risk of graft failure, but raises the risk of significant bleeding.
Transcatheter Therapies for the Tricuspid Valve: Where Are We Today?
Columbia and Weill Cornell Medicine structural heart disease faculty offer the latest clinical trials to treat tricuspid valve regurgitation.
Of PRIMARY Importance: Surgical or Percutaneous Repair for Mitral Regurgitation?
Columbia is a study site for the PRIMARY trial, which will answer critical questions about open surgery compared to transcatheter mitral valve repair for younger patients or patients at lower or intermediate risk for undergoing open surgery.
The Link Between COVID-19 and Arrhythmias
Weill Cornell Medicine researchers co-led a new pre-clinical trial finding that SARS-CoV-2 can infect pacemaker cells, inducing ferroptosis and leading to abnormal heart rhythms.
Multi-Arterial CABG: The Odyssey of the Radial Artery as a Second Conduit
A cardiothoracic surgeon at Weill Cornell Medicine is an ongoing pioneer in research on multiple arterial grafting for coronary artery bypass surgery.
Probing the Predictive Capability of a Next Generation Implantable Cardiac Monitor
Dr. Elaine Wan, a Columbia invasive cardiac electrophysiologist, is serving as one of two national Principal Investigators on a major clinical trial investigating an implantable loop recorder to detect heart failure events
Aortic Valve Regurgitation: Why Surgical Management Remains in Vogue
NewYork-Presbyterian/Columbia heart surgeons present a detailed analysis of surgical outcomes in patients with aortic insufficiency.
Reducing Risk of Atrial Fibrillation After Cardiac Surgery
Weill Cornell Medicine faculty establish the potential of posterior left pericardiotomy performed during heart surgery to reduce the subsequent incidence of atrial fibrillation.
A Closer Look at Cardiac Resynchronization Therapy in Patients with LVADs
Heart failure specialists at NewYork-Presbyterian Hospital have conducted the first prospective randomized study of cardiac resynchronization therapy in patients with an LVAD.
Introducing Ultrasound to Control Drug-Resistant Hypertension
Columbia University interventional cardiologists at NewYork-Presbyterian Hospital are spearheading an international clinical trial that is evaluating the benefit of ultrasound renal denervation for patients with resistant hypertension.
Tackling Cardiometabolic Diseases at the Molecular Level
Weill Cornell Medicine faculty are investigating molecular mechanisms of cardiometabolic diseases – from the mouse model to human biology – with the goal of developing novel treatments to prevent diabetic and cardiac complications.
Addressing Heart Complications of COVID-19
A study by faculty at Weill Cornell Medicine and Columbia University uncover the source of cardiac damage in patients with COVID-19 and also identify FDA drug candidates as potential therapies.
Centralized Heart Failure Management Program Using Remote Monitoring, Artificial Intelligence
Led by Nir Uriel and Gabriel Sayer, NewYork-Presbyterian developed a 5-phase approach to identify patients with worsening heart failure who may benefit from heart failure management in between clinic visits.
Management of Heart Transplant Recipients Infected With SARS-COV2
Heart transplant recipients with COVID-19 are at high risk for severe complications. The researchers, led by Nir Uriel, MD, MSc, discuss implications for the management of SARS-COV2, given the need for immunosuppression in this patient population.
Advanced Heart Failure: Pursuing Progress on Many Fronts
From remote home monitoring to the latest medical therapies, ventricular assist devices, and heart transplantation, NewYork-Presbyterian’s cardiologists and surgeons offer the most advanced medical and surgical options to patients who have many forms of advanced cardiac disease.
Extending the Reach of Transcatheter Therapies
With the great successes of TAVR, transcatheter therapies are emerging for other types of structural heart disease, including aortic regurgitation and disorders of the mitral and triscuspid valves. At the same time, studies continue underway to further enhance these procedures.
A Minimally Invasive Device for Total Aortic Arch Repair
Cardiac and vascular surgeons at NewYork-Presbyterian Hospital have come together for a groundbreaking trial to evaluate the first device for a complete aortic arch endovascular replacement available in the United States.
Novel Therapies in Electrophysiology
Patients with heart failure and patients with congenital heart disease can present with structural anomalies that make them poor candidates for traditional treatments for arrhythmias. At NewYork-Presbyterian Hospital, electrophysiologists are studying alternative methods for overcoming challenges to regulating heart rhythm in these patients.
Clinical Considerations in Prosthetic Aortic Graft Replacement
Cardiothoracic surgeons and cardiologists at NewYork-Presbyterian Hospital provide insight into proximal aortic surgery, a lifesaving procedure for patients with ascending aortic aneurysms.
Transcatheter Trials Break New Ground
Promising catheter-based treatments under evaluation in multiple clinical trials are bringing help and hope to patients with severe mitral valve and tricuspid valve disease. At the forefront of these studies are the heart teams of NewYork-Presbyterian Hospital, where transcatheter therapies are in great demand.
Left Ventricular Remodeling and Its Reversal
Heart failure specialists at NewYork-Presbyterian Hospital examine the range of therapeutic options for heart failure caused by left ventricular remodeling. Their in-depth article in Structural Heart focuses on treatments that have been successful in preventing or reversing remodeling biological and physical approaches.
TAA Repair and Coronary Surgical Practices: Cardiac Surgeons Present Compelling Research
Cardiothoracic surgeons at NewYork-Presbyterian report on new approaches to address daunting complications with open thoracoabdominal aneurysm repair and the ongoing debate on the adoption of coronary surgery as a super specialty.
Mitral Valve Disease: The Treatment Evolution Continues
NewYork-Presbyterian heart teams are spearheading the latest trials in transcatheter repair and replacement to minimize the risks and maximize the outcomes for patients with complex mitral valve disease.
At #4 in the Nation, Elevating Cardiac Care Continues
NewYork-Presbyterian/Columbia University Irving Medical Center’s renowned cardiology and cardiac surgery program is advancing the field through our groundbreaking work in TAVR, adult congenital heart disease, sports cardiology, and obestrical cardiology programs.
Dr. Nir Uriel: Elevating Progress in Advanced Heart Failure
Dr. Nir Uriel, an internationally recognized leader in heart failure, mechanical circulatory support, and heart transplantation, will oversee heart failure programs at NewYork-Presbyterian’s campuses in Manhattan, Queens, Brooklyn, and Westchester.
Noteworthy Progress in LVAD Therapy: The HeartMate3
The FDA approved the HeartMate 3™ left ventricular assist device (LVAD) as a destination therapy for patients with advanced heart failure who are not eligible for transplant, as a life-long implant.
Pursuing Progress in Pulmonary Hypertension
Among the largest programs in the world for pulmonary hypertension, the Pulmonary Hypertension Centers of NewYork-Presbyterian manage some of the most complicated and sickest patients with this rare, progressive cardiopulmonary disease.
Mitral Valve Disease: Maximizing Outcomes with Teamwork and New Technology
Cardiologists, interventional cardiologists, and cardiac surgeons at NewYork-Presbyterian bring their expertise to bear in colla¬borations that allow the details of the patient’s disease to dictate the best treatment.
TAVR Branches Out: New Refinements, Broader Indications
In the years since the first transcatheter aortic valve replacement (TAVR) was performed, the interventional cardiologists and cardiac surgeons at NewYork-Presbyterian have made inroads in device technologies and patient selection.
Adult Congenital Heart Disease Comes of Age
With the number of adult congenital heart disease patients exceeding the number of pediatric aged patients, clinicians at the Congenital Heart Center of NewYork-Presbyterian Hospital are charged with providing care for this unique patient population.
Newsletters for Medical Professionals
2023 Issue 2
- Women Fare Worse than Men Undergoing CABG: Time to Close the Gap
- NewYork-Presbyterian Researchers Are Getting to the Heart of the Fight-or-Flight Response
2023 Issue 1
- Identifying the Finer Points of Aortic Valve-Sparing Root Replacement
- For Women Only: A Study of Intravascular Lithotripsy for Coronary Artery Calcification
2022 Issue 3
2022 Issue 2
- Hypertrophic Cardiomyopathy: The Role for Septal Myectomy
- Pulmonary Hypertension: How MRI Can Help Get to the Heart of the Matter
2022 Issue 1
- Retrograde Cerebral Perfusion: Heightening Protection During Aortic Arch Surgery
- Wave of the Future: Remote Cardiac Monitoring for Heart Failure
2021 Issue 3
2021 Issue 2
2021 Issue 1
2020 Issue 1
- Merging Surgical Expertise to Uproot Cardiac Sarcomas
- A Novel Shunt Approach Shows Promise for End-Stage Pulmonary Arterial Hypertension
- Dr. Mitchell Elkind Named President of American Heart Association
2019 Issue 2
- Dr. Nir Uriel: Elevating Progress in Advanced Heart Failure
- Dr. Stephanie Mick: Spearheading Minimally Invasive Cardiac Procedures
- TAVR Marks Another Milestone
- Dr. Martin B. Leon Recognized with American College of Cardiology’s Top Honor
2019 Issue 1
- Research Highlights Targeting Challenges in Cardiovascular Disease:
2018 Issue 3
2018 Issue 2
- Opening New Channels of Research in Heart Disease
- Ryanodine Receptor: Another Channel Implicated in Heart Disease
2018 Issue 1
- Mitral Valve Disease: Maximizing Outcomes with Teamwork and New Technology
- Current Clinical Trials for Transcatheter Mitral Valve Repair
2017 Issue 1
- TAVR Branches Out: New Refinements, Broader Indications